Produit
AGENTS IA
APPLICATIONS DE L'IA
AUTRES
Solutions
SECTEURS D'ACTIVITÉ
USE CASES
Tarification
Ressources
EXPLORER
ENGAGER
ASSISTANCE ET SERVICES
À propos
Plateforme PatSnap Eureka
Mandataires en propriété intellectuelle
Agents pour l'ingénierie
Agents pour les sciences de la vie
Agents pour matériaux
PatSnap Eureka Desktop
NEWAnalytique
Intelligence IPSynapse
Renseignement biopharmaceutiqueBiographie
Recherche et analyse de séquences biologiquesChimique
Recherche et analyse de structures chimiquesPlateforme ouverte
NEWServices professionnels
Cabinets d'avocats
Sciences de la vie
Haute technologie
Competitor Tech Research
Design Risk Screening
Cosmetic Formulation
Telecom SEP Claim Chart
Accès à plus de 2 000 000 000 points de données structurées dans les domaines des brevets, des sciences, des litiges et des technologies.
Innovez 75 % plus vite à un coût réduit de 25 %.
Cloud ou sur site pour une confidentialité et un contrôle maximaux
Reconnu par plus de 18 000 innovateurs à travers le monde
Pour l'utiliser, cliquez sur le bouton de vérification dans l'e-mail que nous avons envoyé à [email protected].
Cela contribue à sécuriser votre compte.
Vous devriez le recevoir sous peu. N'oubliez pas de vérifier votre dossier spam.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Série soigneusement sélectionnée offrant des informations précieuses aux professionnels de l'innovation.
Article | Rapport How do test-time compute scaling and parameter scaling differ for AI reasoning benchmarks? A technical analysis of mechanisms, saturation, and causal reasoning.
Article | Rapport Explore the JIA drug pipeline: IL-17, IL-6, and JAK inhibitor approaches in pediatric autoimmune disease, from patent filings to off-label clinical signals.
Article | Rapport Phage therapy is staging a global comeback. Explore the 2026 patent landscape, AI-driven innovation clusters, and strategic IP white space in bacteriophage therapeutics.
Article | Rapport How Power-to-X technology couples renewable electricity with chemical feedstock production — pathways, steel & chemicals applications, reactor engineering, and key patents.
Article | Rapport Optical computing interconnect patents and research 2026: silicon photonics, co-packaged optics, FSO, and fiber switching — mapped across hyperscalers, chipmakers, and academia.
Article | Rapport How Power-to-X technology couples renewable electricity with chemical feedstock production for industrial decarbonization — pathways, patents, and key players analysed.
Article | Rapport Pediatric NAFLD drug pipeline: PNPLA3 targeting, GLP-1 agonists, DHA, and lifestyle interventions mapped across preclinical and clinical evidence. Read the full analysis.
Article | Rapport sCO2 Brayton cycle vs organic Rankine cycle for industrial waste heat recovery: efficiency data, temperature ranges, cost trade-offs, and hybrid configurations explained.
Article | Rapport The μSOFC technology landscape in 2026: operating temperatures down to 350°C, 812 mW cm⁻² power density, and emerging IP white space in metal substrates and additive manufacturing.
Article | Rapport Next-generation SSA, alpha-emitter PRRT, and mTOR combination strategies in the NET drug pipeline — patent signals, clinical data, and emerging IP white spaces.
Article | Rapport sCO2 Brayton cycle vs organic Rankine cycle for industrial waste heat recovery: thermodynamic performance, temperature ranges, compactness, economics, and hybrid configurations compared.
Article | Rapport Explore the 2026 hydrophobic surface coating technology landscape: key innovation clusters, application domains, geographic leaders, and emerging directions from 80+ records.
Article | Rapport How do automotive fuel cell stacks maintain proton exchange membrane hydration under dynamic load cycling? Engineering analysis of flooding, drying, fatigue, and control.
Article | Rapport CDK4/6 inhibitors, MDM2 antagonists, and histotype-specific strategies are reshaping the soft tissue sarcoma drug pipeline. Explore the latest preclinical and clinical evidence.
Article | Rapport PeLEDs now exceed 28% EQE and 30,000-hour lifetimes. Explore the 2026 perovskite LED landscape: key materials, efficiency records, and commercialisation signals.